

State of California—Health and Human Services Agency Department of Health Care Services



EDMUND G. BROWN JR. GOVERNOR

DEC 0 1 2014

Hye Sun Lee Acting Associate Regional Administrator Division of Medicaid and Children's Health Operations Centers for Medicare and Medicaid Services San Francisco Regional Office 90 Seventh Street, Suite 5-300 (5W) San Francisco, CA 94103-6707

Dear Ms. Lee:

State Plan Amendment (SPA) 14-034, "Supplemental Drug Rebate Agreements", is being proposed by the Department of Health Care Services (DHCS) with a requested effective date of October 1, 2014, and is enclosed for your review and approval.

SPA 14-034 updates the definition of 'Medi-Cal Utilization Data' in both the Medi-Cal Average Manufacturer Price (AMP) Supplemental Drug Rebate Agreement and the Medi-Cal Net Cost Supplemental Drug Rebate Agreement to have the same meaning as 'utilization data' as described in California Welfare and Institutions Code Section 14105.33. The new language gives DHCS the ability to collect state supplemental drug rebates from Managed Care Organizations.

The SPA also clarifies, in both state supplemental drug rebate agreements, that if Federal Upper Limit (FUL) or Maximum Allowable Ingredient Cost (MAIC) prices are implemented for product(s) covered by the agreement that a contractor shall not pay a state supplemental rebate for those covered product(s). Other non-substantive changes include, but are not limited to, name changes of DHCS, divisions, titles of personnel, and address changes since the last version of the State Plan.

Since the changes proposed by this SPA will not "further restrict eligibility; or reduce payment rates or make updates to payment methodologies to Indian health programs; or reduce or restrict access to covered services; or increase services reimbursed to Indian health programs; or update the tribal consultation policy in any way," a tribal notice was deemed not required for this SPA. Ms. Lee Page 2

For questions or comments please contact Mr. Harry Hendrix, Chief, Pharmacy Benefits Division, at (916) 552-9608 or by e-mail at <u>harry.hendrix@dhcs.ca.gov</u>.

# Original Signed

Director

Enclosures

DEPARTMENT OF HEALTH AND HUMAN SERVICES HEALTH CARE FINANCING ADMINISTRATION		FORM APPROVED OMB NO. 0938-0193
TRANSMITTAL AND NOTICE OF APPROVAL OF	1. TRANSMITTAL NUMBER:	2. STATE
STATE PLAN MATERIAL	14-034	CA
FOR: HEALTH CARE FINANCING ADMINISTRATION	3. PROGRAM IDENTIFICATION: TIT SOCIAL SECURITY ACT (MEDICA	
TO: REGIONAL ADMINISTRATOR	4. PROPOSED EFFECTIVE DATE	
HEALTH CARE FINANCING ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES	10/1/2014	
5. TYPE OF PLAN MATERIAL <i>(Check One)</i> :	10/11/2011	
	CONSIDERED AS NEW PLAN	AMENDMENT
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AME	NDMENT (Separate Transmittal for each	amendment)
6. FEDERAL STATUTE/REGULATION CITATION:	7. FEDERAL BUDGET IMPACT:	
42 U.S.C. 1396r–8	a. FFY 14-15 \$0	
	b. FFY 15-16 \$0	
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:	9. PAGE NUMBER OF THE SUPERSI	
	OR ATTACHMENT (If Applicable):	
Supplement 2 to Attachment 4.19-B, pages 6, 7, 12-37	Supplement 2 to Attachment 4.19-B, pages 6, 7, including the	
	appended Medi-Cal Average Manufactu	
	Drug Rebate Agreement, pages 1-6 and	
	Cost Drug Rebate Agreement, pages 1-5	
	rebate contract template pages are not m	umbered as part of the
	state plan.)	
10. SUBJECT OF AMENDMENT:		

Modify state supplemental drug rebate agreements to give the Department of Health Care Services the ability to collect supplemental drug rebates from Managed Care Organizations in accordance with California Welfare and Institutions Code 14105.33.

#### 11. GOVERNOR'S REVIEW (Check One):

GOVERNOR'S OFFICE REPORTED NO COMMENT

COMMENTS OF GOVERNOR'S OFFICE ENCLOSED

NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL

⊠OTHER, AS SPECIFIED:

The Governor's Office does not wish to review the State Plan Amendment

Original Signed		16. RETURN TO:
Toby Douglas 14. TITLE: Director	<b>DEC 0 1</b> 2014	Department of Health Care Services Attn: State Plan Coordinator 1501 Capitol Avenue, MS 4506 P.O. Box 997419
15. DATE SUBMITTED:		Sacramento, CA 95899-7419

FOR REGIONAL OFFICE USE ONLY		
17. DATE RECEIVED:	18. DATE APPROVED:	
PLAN APPROVED – ONE	E COPY ATTACHED	
19. EFFECTIVE DATE OF APPROVED MATERIAL:	20. SIGNATURE OF REGIONAL OFFICIAL:	
21. TYPED NAME:	22. TITLE:	

23. REMARKS:

I. The State Agency believes reimbursement to long-term pharmacy providers to be consistent and reasonable with costs reimbursed to other providers. The State Agency maintains an advisory committee known as the Medi-Cal Contract Drug Advisory Committee in accordance with Federal law. STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT STATE: California

METHODS AND STANDARDS FOR ESTABLISHING PAYMENT RATES -PRESCRIBED DRUGS

This Page Intentionally Left Blank

#### DRUG REBATE PROGRAM

The State Agency is in compliance with Section 1927 of the Social Security Act. The State Agency reimburses providers of drugs of manufacturers participating in the drug rebate program and is in compliance with reporting requirements for utilization and restrictions to coverage. Pharmaceutical manufacturers can audit utilization data to the extent allowed under the Health Insurance Portability and Accountability Act (HIPAA) in order to ensure that the Department is protecting information in accordance with HIPAA. The unit rebate amount is confidential and is not disclosed to anyone not entitled to the information for purposes of rebate contracting, invoicing and verification.

#### SUPPLEMENTAL REBATE PROGRAM

The State Agency negotiates supplemental rebates in addition to the federal rebates provided for in Title XIX. Rebate agreements between the state and a pharmaceutical manufacturer are separately identified from the federal rebates.

Supplemental rebates received by the State Agency in excess of those required under the national drug rebate agreement are shared with the Federal government on the same percentage basis as applied under the national rebate agreement. CMS has authorized the State of California to enter into the Medi-Cal Supplemental Drug Rebate Average Manufacturer Price (AMP) Agreement. This supplemental drug rebate agreement was submitted to CMS on <u>(Insert date)</u> and has been authorized by CMS. CMS has authorized the State of California to enter into the Medi-Cal Net Cost Supplemental Drug Rebate Agreement. This supplemental drug rebate agreement was submitted to CMS on <u>(Insert date)</u> and has been authorized by CMS.

Approval Date: \_\_\_\_

by the program, notwithstanding a prior authorization agreement, will comply with the provisions of the national drug rebate agreement.

# MEDI-CAL AVERAGE MANUFACTURER PRICE SUPPLEMENTAL DRUG REBATE AGREEMENT

This Agreement is made and entered into this \_\_\_\_\_ day of \_\_\_\_\_\_ 20\_\_\_, by and between the State of California (State), represented by the Department of Health Care Services (Department), and <u>(FULL, LEGAL NAME OF COMPANY)</u> (Contractor), Labeler Code <u>00000</u>. The parties, in consideration of the covenants, conditions, agreements, and stipulations expressed in this Agreement, do agree as follows:

#### ARTICLE I - PREAMBLE

1.1 It is the intent of this Agreement that, pursuant to Welfare and Institutions Code Sections 14105.31 and 14105.33, the Department will receive a Rebate for Contractor's Covered Product(s), including a State Supplemental Rebate, and that the Department will (add/retain) Contractor's Covered Product(s) (to/on) the Medi-Cal List of Contract Drugs. The parties also intend for this Agreement to meet the requirements of federal law at Title 42 United States Code Section 1396r-8.

#### **ARTICLE II - DEFINITIONS**

2.1 'Average Manufacturer Price' (AMP) and 'Best Price' means the Contractor's price(s) for the Covered Product(s) as these terms are defined pursuant to Section 1927 of the Social Security Act [42 USC 1396r-8] and calculated as specified in Contractor's CMS Agreement.

## 2.2 'Covered Product(s)' means the pharmaceutical product(s) [CHEMICAL ENTITY (REGISTERED TRADEMARK NAME®), DOSAGE FORM, STRENGTH].

- 2.3 'CMS Agreement' means the Contractor's drug rebate contract with the Centers for Medicare and Medicaid Services (CMS), entered pursuant to Section 1927 of the Social Security Act (42 USC 1396r-8).
- 2.4 'CMS Basic Rebate' means, with respect to the Covered Product(s), the quarterly payment by Contractor pursuant to Contractor's CMS Agreement, made in accordance with Section 1927(c)(1) or Section 1927(c)(3) of the Social Security Act [42 USC 1396r-8(c)(1) and 42 USC 1396r-8(c)(3)].
- 2.5 'CMS CPI Rebate' means, with respect to the Covered Product(s), the quarterly payment by Contractor pursuant to Contractor's CMS Agreement, made in accordance with Section 1927(c)(2) of the Social Security Act [42 USC 1396r-8(c)(2)].
- 2.6 'Medi-Cal Utilization Data' has the same meaning as 'utilization data' as described in Welfare and Institutions Code section 14105.33.
- 2.7 'Rebate' means, with respect to the Covered Product(s), the quarterly payment by Contractor pursuant to Article III, Sections 3.1 and 3.2 of this Agreement.
- 2.8 'Rebate Summary' means the report itemizing the Medi-Cal Utilization Data supporting the Department's invoice for Rebates. The Rebate Summary will comply in all respects with requirements for Medicaid Utilization Information in the CMS Agreement.

2.9 'State Supplemental Rebate' means, with respect to the Covered Product(s), the quarterly payment by Contractor pursuant to Article III, Section 3.2 of this Agreement.

#### **ARTICLE III - CONTRACTOR'S RESPONSIBILITIES**

- 3.1 Contractor will provide the Department a Rebate for the Covered Product(s), which includes the CMS Basic Rebate and CMS CPI Rebate, as appropriate. The CMS rebates represent the discount obtained by multiplying the units of the Covered Product(s) reimbursed by the Department in the preceding quarter by the per unit rebate amount provided to the Department by CMS. CMS will calculate the rebate amount in accordance with Contractor's CMS Agreement. Contractor's OMS Agreement.
- 3.2 In addition to the Rebates described in Section 3.1 of this Agreement, Contractor will remit to the Department a State Supplemental Rebate for the Covered Product(s) calculated as \_\_\_\_ percent of Contractor's AMP for the Covered Product(s). Contractor shall submit to the Department, on a quarterly basis, the AMP for each National Drug Code (NDC) number for each Covered Product. Such data shall be provided in the format and timeframe specified by the Department. Contractor agrees, pursuant to Welfare and Institutions Code Section 14105.332, that Rebates payable under this section shall not be reduced if the Contractor reports to CMS or the Department, a revised AMP or Best Price for any calendar quarter in which the rebate was due. In addition, the Contractor will remit an additional supplemental rebate payment equal to the difference

between the initial CMS rebate paid and any revised CMS rebate amounts, as described in 3.1, should the rebate revision result in a reduction in the amount payable as these terms are defined pursuant to Section 1927 of the Social Security Act [42 USC 1396r-8]. The State Supplemental Rebate represents the discount obtained by multiplying the units of each Covered Product reimbursed by the Department in the preceding quarter by the applicable per unit amount specified above for each Covered Product for the same guarter. Contractor's obligation for State Supplemental Rebates will begin with the rebate billing period for first, second, third, fourth quarter (Insert Year) which begins DATE GENERALLY SHOULD BE THE START OF A CALENDAR QUARTER, and will continue through the quarter that ends **DATE GENERALLY COINCIDES WITH** THE END DATE OF THE CONTRACT IN SECTION 5.9. If CMS establishes and the Department implements Federal Upper Limit prices, or if the Department establishes and implements Maximum Allowable Ingredient Cost prices on any strengths of the Covered Product(s), Contractor shall pay no State Supplemental Rebate for those strengths of the Covered Product(s) commencing with the beginning of the guarter in which the Federal Upper Limit price or Maximum Allowable Ingredient Cost price is implemented.

- 3.3 The quarters to be used for calculating the Rebates in Sections 3.1 and 3.2 of this Agreement will be those ending on March 31, June 30, September 30, and December 31 of each calendar year during the term of this Agreement.
- 3.4 Contractor will assist the Department in developing annual estimates of aggregate Rebates for the Department's budgetary purposes.

- 3.5 Contractor will pay the Rebates, including any applicable interest in accordance with Welfare and Institutions Code Sections 14105.31 and 14105.33(k) - (u), and federal laws, regulations, and/or guidelines. Interest on the Rebates payable under Section 3.1 and 3.2 of this Agreement begins accruing 38 calendar days from the postmark date of the Department's invoice and supporting utilization data sent to the Contractor and interest will continue to accrue until the postmark date of the Contractor's payment. For Rebates invoiced for first, second, third, fourth calendar guarter (Insert year), and thereafter, if the date of mailing of the Rebate payable under Section 3.2 of this Agreement is 69 days or more from the date of mailing of the invoice, the interest rate will be calculated as required under federal guidelines, but will be increased by ten percentage points. For Rebates invoiced for first, second, third, fourth calendar quarter (Insert year), and thereafter, if the Department has not received the Rebates payable under Section 3.1 or 3.2 of this Agreement, including interest, within 180 days of the postmark date of the Department's invoice and supporting utilization data sent to the Contractor, this Agreement will be deemed to be in default and will be terminated in accordance with Section 5.11 of this Agreement.
- 3.6 With each quarterly remittance, Contractor will submit a Form CMS-304 (Reconciliation of State Invoice), consistent with federal requirements, and a separate Form CMS-304 for the State Supplemental Rebate. In the event that in any quarter any material discrepancy is discovered by Contractor, which Contractor in good faith is unable to resolve, Contractor will provide written notice of the discrepancy to the Department. The Department and Contractor will use their best efforts to resolve the discrepancy within 90 days of receipt by the Department of the notification.

- 3.7 If Contractor in good faith believes the amount claimed in the Rebate Summary is erroneous, Contractor may pay the Department only that portion of the amount claimed which is not disputed. Upon resolution of the dispute, any balance will be paid by Contractor promptly; any overpayment will be credited against the next payment due, if any.
- 3.8 Contractor agrees to continue to pay a Rebate on the Covered Product(s) for as long as this Agreement is in force, and Medi-Cal Utilization Data shows that payment was made for that drug, regardless of whether the Contractor continues to market that drug.
- 3.9 Unless notified otherwise, Contractor will send Rebate payments to the following address:

Department of Health Care Services Accounting Section 1501 Capitol Avenue, Suite 2048, MS 1101 Sacramento, CA 95814

#### ARTICLE IV - DEPARTMENT RESPONSIBILITIES

- 4.1 The Department will (add/retain) the Covered Product(s) (to/on) the Medi-Cal List of Contract Drugs. (ADD STATEMENT REGARDING EXCLUSIVITY OR CODE I RESTRICTIONS, IF APPLICABLE).
- 4.2 The Department will provide Medi-Cal Utilization Data to Contractor on a quarterly basis. This data will be based on paid claims data (data used to reimburse providers) under the Medi-Cal program, will be consistent with any applicable Federal or State guidelines, regulations and standards for such data, and will be the basis for the Department's calculation of the Rebate.
- 4.3 The Department will maintain those data systems and audits as are necessary to ensure the accuracy of the data used to calculate the Rebate. In the event material discrepancies are discovered, the Department will promptly justify its data or make an appropriate adjustment which may include a credit as to the amount of the Rebate or a refund to Contractor as the parties may agree.
- 4.4 Upon implementation of this Agreement, and from time to time thereafter, the Department and Contractor will meet to discuss any data or data system improvements which are necessary or desirable to ensure that the data and any information provided by the Department to Contractor are adequate for the purposes of this Agreement.
- 4.5 The Department will provide Contractor with a copy of the independent auditor's report of the Electronic Data Processing Application Systems Audit of the Department's fiscal intermediary for Medi-Cal Utilization Data. In the event

Approval Date: \_\_\_\_

material discrepancies are discovered by the auditor, the Department will promptly justify its data or make an appropriate adjustment.

#### **ARTICLE V - GENERAL PROVISIONS**

- 5.1 This Agreement will be governed and construed in accordance with: (a) Part 3, Division 9 of the Welfare and Institutions Code; Division 3 of Title 22 of the California Code of Regulations; and all other applicable State law and regulations; and (b) Title 42 United States Code Section 1396; Title 42 of the Code of Federal Regulations; and all other applicable federal law and regulations.
- 5.2 Any notice required to be given pursuant to the terms and provisions of this Agreement will be in writing and will be sent by certified mail, return receipt requested. Notice to the Department will be sent to:

California Department of Health Care Services Pharmacy Benefits Division 1501 Capitol Avenue, Suite 71.5131, MS 4604 Sacramento, CA 95814

Notice to Contractor will be sent to:

 (NAME)
 _(TITLE)
 (COMPANY NAME)
 (ADDRESS)

Approval Date: \_\_\_\_

- 5.3 Pursuant to 42 USC 1396r-8(b)(3)(D), the parties agree that confidential information will not be disclosed. Pursuant to Welfare and Institutions Code Section 14105.33(h) and Evidence Code Section 1060, the parties agree that the terms of this Agreement are confidential and exempt from disclosure under the California Public Records Act at Chapter 3.5 (commencing with Section 6250) of Division 7 of Title 1 of the Government Code. Each party will treat trade secrets and other confidential information as confidential, will preserve the confidentiality and will not duplicate, disclose or use the information, except in connection with this Agreement or as may be required by judicial order. Notwithstanding the termination of this Agreement for any reason, these confidentiality provisions will remain in full force and effect.
- 5.4 Contractor and the agents and employees of Contractor in the performance of this Agreement, will act in an independent capacity and not as officers or employees or agents of the State of California.
- 5.5 This Agreement is not assignable either in whole or in part without the written consent of the Department, which will not unreasonably be withheld.
- 5.6 Nothing in this Agreement will be construed so as to require the commission of any act contrary to law. If any provision of this Agreement is found to be invalid or illegal by a court of law, or inconsistent with federal requirements, this Agreement will be construed in all respects as if any invalid, unenforceable, or inconsistent provision were eliminated, and without any effect on any other provision. The parties agree to negotiate replacement provisions, to afford the parties as much of the benefit of their original bargain as is possible.

- 5.7 The Department and Contractor declare that this Agreement, including attachments, contains a total integration of all rights and obligations of both parties. There are no extrinsic conditions or collateral agreements or undertakings of any kind. In regarding this Agreement as the full and final expression of their contract, it is the express intention of both parties that any and all prior or contemporaneous agreements, promises, negotiations or representations, either oral or written, relating to the subject matter and period of time governed by this Agreement which are not expressly set forth herein are to have no force, effect, or legal consequences of any kind.
- 5.8 The introductory paragraph and sections 1.1, 2.2, 3.2, 3.5, 4.1, 5.2, and 5.9 of this Agreement will not be altered except by an amendment in writing signed by both parties and approved by the appropriate State control agencies. All other numbered sections of this Agreement will not be altered except by an amendment in writing signed by both parties and approved by the appropriate State control agencies and authorized by the Centers for Medicare and Medicaid Services. No person is authorized to alter or vary the terms or make any representation or inducement relative to it, unless the alteration appears by way of a written amendment, signed by duly appointed representatives of the State and Contractor and approved by the appropriate State control agencies.
- 5.9 This Agreement will be in effect from date of execution through (Insert Date).
- 5.10 The Department intends to implement this contract through a single administrator, called the "Contracting Officer". The Contracting Officer will be appointed by the Director of the Department. The Contracting Officer will make

all determinations and take all actions as are appropriate under this contract on behalf of the Department, subject to the limitations of California law.

- 5.11 This Agreement may be terminated by either party by giving written notice to the other party at least 90 days prior to the effective date of the termination. Termination of this Agreement will result in Contractor's Covered Product being available to Medi-Cal beneficiaries only through prior authorization.
- 5.12 Neither party contemplates any circumstances under which indemnification of the other party would arise. Nevertheless, should such circumstances arise, Contractor agrees to indemnify, defend and hold harmless the State, its officers, agents and employees from any and all claims and losses accruing or resulting to any person, firm or corporation who may be injured or damaged by the Contractor in the performance of this Agreement.
- 5.13 Inasmuch as the State Supplemental Rebate required by this Agreement is only for Medi-Cal beneficiaries, the State Supplemental Rebate does not establish a new 'Best Price' for purposes of Contractor's CMS Agreement.
- 5.14 In the event that the Department determines, as a result of a therapeutic category review, that a Covered Product of the Contractor included on the Medi-Cal list of contract drugs as a consequence of this Agreement should be removed from the list of contract drugs and require prior approval, the parties agree that the terms of Section 5.11 shall apply.

As evidence of their Agreement to the foregoing terms and conditions the parties have signed below.

(Insert Name), Chief	(NAME)
Pharmacy Benefits Division	(TITLE)
Department of Health Care Services,	(COMPANY NAME)
for the State of California	

Dated:\_\_\_\_\_

# MEDI-CAL NET COST SUPPLEMENTAL DRUG REBATE AGREEMENT

This Agreement is made and entered into this \_\_\_\_\_ day of \_\_\_\_\_\_ 20\_\_\_\_, by and between the State of California (State), represented by the Department of Health Care Services (Department), and **(ENTER FULL, LEGAL NAME OF COMPANY)** (Contractor), Labeler Code **00000**. The parties, in consideration of the covenants, conditions, agreements, and stipulations expressed in this Agreement, do agree as follows:

#### **ARTICLE I - PREAMBLE**

1.1 It is the intent of this Agreement that, pursuant to Welfare and Institutions Code Sections 14105.31 and 14105.33, the Department will receive a Rebate for Contractor's Covered Product(s), including a State Supplemental Rebate, and that the Department will (add/retain) Contractor's Covered Product(s) (to/on) the Medi-Cal List of Contract Drugs. The parties also intend for this Agreement to meet the requirements of federal law at Title 42 United States Code Section 1396r-8.

#### **ARTICLE II - DEFINITIONS**

2.1 'Estimated Acquisition Cost' (EAC) means the highest cost of the drug, pursuant to Welfare and Institutions Code, Section 14105.45, during the calendar quarter that corresponds to the calendar quarter for which the Medi-Cal Utilization Data for the Covered Product(s) is reported to Contractor by the Department in the applicable Rebate Summary.

# 2.2 'Covered Product(s)' means the pharmaceutical product(s) [CHEMICAL NAME (REGISTERED TRADEMARK NAME), DOSAGE FORM, STRENGTH].

- 2.3 'CMS Agreement' means the Contractor's drug rebate contract with the Centers for Medicare and Medicaid Services (CMS), entered pursuant to Section 1927 of the Social Security Act (42 USC 1396r-8).
- 2.4 'CMS Basic Rebate' means, with respect to the Covered Product(s), the quarterly payment by Contractor pursuant to Contractor's CMS Agreement, made in accordance with Section 1927(c)(1) or Section 1927(c)(3) of the Social Security Act (42 USC 1396r-8(c)(1) and 42 USC 1396r-8(c)(3)).
- 2.5 'CMS CPI Rebate' means, with respect to the Covered Product(s), the quarterly payment by Contractor pursuant to Contractor's CMS Agreement, made in accordance with Section 1927(c)(2) of the Social Security Act (42 USC 1396r-8(c)(2)).
- 2.6 'Medi-Cal Net Cost' means the prescription drug ingredient reimbursement by NDC for the Covered Product(s) paid by the Department to Medi-Cal providers during a calendar quarter calculated as the EAC of the drug, minus the sum of all Rebates paid by Contractor to the Department for the Covered Product(s) for the same calendar quarter pursuant to Article III, Section 3.1 and 3.2 of this Agreement. In the event of any change to the calculation used by the Department to Medi-Cal providers, the parties may elect to renegotiate the terms of this Agreement pursuant to Section 5.8.

- 2.7 'Medi-Cal Utilization Data' has the same meaning as 'utilization data' as described in Welfare and Institutions Code section 14105.33.
- 2.8 'Rebate' means, with respect to the Covered Product(s), the quarterly payment by Contractor pursuant to Article III, Sections 3.1 and 3.2 of this Agreement. It also means equalization payment as used in Welfare and Institutions Code Section 14105.31(c).
- 2.9 'Rebate Summary' means the report itemizing the Medi-Cal Utilization Data supporting the Department's invoice for Rebates. The Rebate Summary will comply in all respects with requirements for Medicaid Utilization Information in the CMS Agreement.
- 2.10 'State Supplemental Rebate' means, with respect to the Covered Product(s), the quarterly payment by Contractor pursuant to Article III, Section 3.2 of this Agreement.

#### **ARTICLE III - CONTRACTOR'S RESPONSIBILITIES**

- 3.1 Contractor will provide the Department a Rebate for the Covered Product(s), which includes the CMS Basic Rebate and CMS CPI Rebate, as appropriate. The CMS rebates represent the discount obtained by multiplying the units of the Covered Product(s) reimbursed by the Department in the preceding quarter by the per unit rebate amount provided to the Department by CMS. CMS will calculate the rebate amount in accordance with Contractor's CMS Agreement. Contractor's obligation for Rebates will continue for the duration of the Contractor's CMS Agreement.
- 3.2 In addition to the Rebates described in Section 3.1 of this Agreement, Contractor will remit to the Department a State Supplemental Rebate for the Covered Product(s) such that the Medi-Cal Net Cost of the Covered Product(s) will be (\$x.xx) per (specify unit - gm, ml, tablet, etc) or a lower Medi-Cal Net Cost which may be generated by Contractor's CMS Agreement. Contractor's obligation for State Supplemental Rebates will begin with the rebate billing period for first, second, third, fourth quarter year which begins DATE GENERALLY SHOULD BE THE START OF A CALENDAR QUARTER, and will continue through the quarter that ends **DATE GENERALLY COINCIDES WITH THE END DATE OF THE CONTRACT IN SECTION 5.9**. If CMS establishes and the Department implements Federal Upper Limit prices, or if the Department establishes and implements Maximum Allowable Ingredient Cost prices on any strengths of the Covered Product(s), Contractor shall pay no State Supplemental Rebate for those strengths of the Covered Product(s) commencing with the beginning of the guarter in which the Federal Upper Limit price or Maximum Allowable Ingredient Cost price is implemented.

- 3.3 The quarters to be used for calculating the Rebates in Section 3.1 and 3.2 of this Agreement will be those ending on March 31, June 30, September 30, and December 31 of each calendar year during the term of this Agreement.
- 3.4 Contractor will assist the Department in developing annual estimates of aggregate Rebates for the Department's budgetary purposes.
- 3.5 Contractor will pay the Rebates, including any applicable interest on late Rebate payments, in accordance with Welfare and Institutions Code Sections 14105.31 and 14105.33(k) - (u), and federal laws, regulations, and/or guidelines. Interest on Rebates payable under Section 3.1 of this Agreement begins accruing 38 calendar days from the postmark date of the Department's invoice and supporting utilization data sent to the Contractor, and interest will continue to accrue until the postmark date of the Contractor's payment. For State Supplemental Rebates payable under Section 3.2 of this Agreement, interest is only applicable to invoices for first, second, third, fourth calendar quarter year. and thereafter, and if the date of mailing of the Rebate payable under Section 3.2 of this Agreement is 69 days or more from the date of mailing of the invoice, the interest rate will be calculated as required under federal guidelines, but will be increased by ten percentage points. For Rebates invoiced for first, second, third, fourth calendar quarter year, and thereafter, if the Department has not received the Rebates payable under Section 3.1 or 3.2 of this Agreement, including interest, within 180 days of the postmark date of the Department's invoice and supporting utilization data sent to the Contractor, this Agreement will be deemed to be in default and will be terminated in accordance with Section 5.11 of this Agreement.

- 3.6 With each quarterly remittance, Contractor will submit a Form CMS-304 (Reconciliation of State Invoice), consistent with federal requirements, and a separate Form CMS-304 for the State Supplemental Rebate. In the event that in any quarter any material discrepancy is discovered by Contractor, which Contractor in good faith is unable to resolve, Contractor will provide written notice of the discrepancy to the Department. The Department and Contractor will use their best efforts to resolve the discrepancy within 90 days of receipt by the Department of the notification.
- 3.7 If Contractor in good faith believes the amount claimed in the Rebate Summary is erroneous, Contractor may pay the Department only that portion of the amount claimed which is not disputed. Upon resolution of the dispute, any balance will be paid by Contractor promptly; any overpayment will be credited against the next payment due, if any.
- 3.8 Contractor agrees to continue to pay a Rebate on the Covered Product(s) for as long as this Agreement is in force, and Medi-Cal Utilization Data shows that payment was made for that drug, regardless of whether the Contractor continues to market that drug.
- 3.9 Unless notified otherwise, Contractor will send Rebate payments to the following address:

Department of Health Care Services Accounting Section 1501 Capitol Avenue, Suite 2048, MS 1101 Sacramento, CA 95814

#### **ARTICLE IV - DEPARTMENT RESPONSIBILITIES**

- 4.1 The Department will (add/retain) the Covered Product(s) (to/on) the Medi-Cal List of Contract Drugs. (ENTER HERE A STATEMENT REGARDING EXCLUSIVITY OR CODE I RESTRICTIONS, IF APPLICABLE).
- 4.2 The Department will provide Medi-Cal Utilization Data to Contractor on a quarterly basis. This data will be based on paid claims data (data used to reimburse providers) under the Medi-Cal program, will be consistent with any applicable Federal or State guidelines, regulations and standards for such data, and will be the basis for the Department's calculation of the Rebate.
- 4.3 The Department will maintain those data systems and audits as are necessary to ensure the accuracy of the data used to calculate the Rebate. In the event material discrepancies are discovered, the Department will promptly justify its data or make an appropriate adjustment which may include a credit as to the amount of the Rebate or a refund to Contractor as the parties may agree.
- 4.4 Upon implementation of this Agreement, and from time to time thereafter, the Department and Contractor will meet to discuss any data or data system improvements which are necessary or desirable to ensure that the data and any information provided by the Department to Contractor are adequate for the purposes of this Agreement.
- 4.5 The Department will provide Contractor with a copy of the independent auditor's report of the Electronic Data Processing Application Systems Audit of the

Department's fiscal intermediary for Medi-Cal Utilization Data. In the event material discrepancies are discovered by the auditor, the Department will promptly justify its data or make an appropriate adjustment.

#### **ARTICLE V - GENERAL PROVISIONS**

- 5.1 This Agreement will be governed and construed in accordance with: (a) Part 3, Division 9 of the Welfare and Institutions Code; Division 3 of Title 22 of the California Code of Regulations; and all other applicable State law and regulations; and (b) Title 42 United States Code Section 1396; Title 42 of the Code of Federal Regulations; and all other applicable federal law and regulations.
- 5.2 Any notice required to be given pursuant to the terms and provisions of this Agreement will be in writing and will be sent by certified mail, return receipt requested. Notice to the Department will be sent to:

California Department of Health Care Services Pharmacy Benefits Division 1501 Capitol Avenue, Suite 71.5131, MS 4604 Sacramento, CA 95814

Notice to Contractor will be sent to:

 (NAME)
 (TITLE)
 (COMPANY NAME)
 (ADDRESS)

Approval Date: \_\_\_\_

- 5.3 Pursuant to 42 USC 1396r-8(b)(3)(D), the parties agree that confidential information will not be disclosed. Pursuant to Welfare and Institutions Code Section 14105.33(h) and Evidence Code Section 1060, the parties agree that the terms of this Agreement are confidential and exempt from disclosure under the California Public Records Act at Chapter 3.5 (commencing with Section 6250) of Division 7 of Title 1 of the Government Code. Each party will treat trade secrets and other confidential information as confidential, will preserve the confidentiality and will not duplicate, disclose or use the information, except in connection with this Agreement or as may be required by judicial order. Notwithstanding the termination of this Agreement for any reason, these confidentiality provisions will remain in full force and effect.
- 5.4 Contractor and the agents and employees of Contractor in the performance of this Agreement, will act in an independent capacity and not as officers or employees or agents of the State of California.
- 5.5 This Agreement is not assignable either in whole or in part without the written consent of the Department, which will not unreasonably be withheld.
- 5.6 Nothing in this Agreement will be construed so as to require the commission of any act contrary to law. If any provision of this Agreement is found to be invalid or illegal by a court of law, or inconsistent with federal requirements, this Agreement will be construed in all respects as if any invalid, unenforceable, or inconsistent provision were eliminated, and without any effect on any other provision. The parties agree to negotiate replacement provisions, to afford the parties as much of the benefit of their original bargain as is possible.

- 5.7 The Department and Contractor declare that this Agreement, including attachments, contains a total integration of all rights and obligations of both parties. There are no extrinsic conditions or collateral agreements or undertakings of any kind. In regarding this Agreement as the full and final expression of their contract, it is the express intention of both parties that any and all prior or contemporaneous agreements, promises, negotiations or representations, either oral or written, relating to the subject matter and period of time governed by this Agreement which are not expressly set forth herein are to have no force, effect, or legal consequences of any kind.
- 5.8 The introductory paragraph and sections 1.1, 2.2, 3.2, 3.5, 4.1, 5.2, and 5.9 of this Agreement will not be altered except by an amendment in writing signed by both parties and approved by the appropriate State control agencies. All other numbered sections of this Agreement will not be altered except by an amendment in writing signed by both parties and approved by the appropriate State control agencies and authorized by the Centers for Medicare and Medicaid Services. No person is authorized to alter or vary the terms or make any representation or inducement relative to it, unless the alteration appears by way of a written amendment, signed by duly appointed representatives of the State and Contractor and approved by the appropriate State control agencies.
- 5.9 This Agreement will be in effect from date of execution through (Insert Date).
- 5.10 The Department intends to implement this contract through a single administrator, called the "Contracting Officer". The Contracting Officer will be appointed by the Director of the Department. The Contracting Officer will make

all determinations and take all actions as are appropriate under this contract on behalf of the Department, subject to the limitations of California law.

- 5.11 This Agreement may be terminated by either party by giving written notice to the other party at least 90 days prior to the effective date of the termination. Termination of this Agreement will result in Contractor's Covered Product(s) being available to Medi-Cal beneficiaries only through prior authorization.
- 5.12 Neither party contemplates any circumstances under which indemnification of the other party would arise. Nevertheless, should such circumstances arise, Contractor agrees to indemnify, defend and hold harmless the State, its officers, agents and employees from any and all claims and losses accruing or resulting to any person, firm or corporation who may be injured or damaged by the Contractor in the performance of this Agreement.
- 5.13 Inasmuch as the State Supplemental Rebate required by this Agreement is only for Medi-Cal beneficiaries, the State Supplemental Rebate does not establish a new 'Best Price' for purposes of Contractor's CMS Agreement.
- 5.14 In the event that the Department determines, as a result of a therapeutic category review, that a Covered Product of the Contractor included on the Medi-Cal list of contract drugs as a consequence of this Agreement should be removed from the list of contract drugs and require prior approval, the parties agree that the terms of Section 5.11 shall apply.

As evidence of their Agreement to the foregoing terms and conditions the parties have signed below.

(NAME)
(TITLE)
(COMPANY NAME)

Dated:\_\_\_\_

Dated: